title: [Therapy of bone metastases with radium-223. German guidelines].
abstract: This document describes the guideline for therapy of bone metastases with radium-223 ((223)Ra) published by the Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften in Germany (AWMF) under the auspices of the Deutsche Gesellschaft für Nuklearmedizin (DGN), Östereichische Gesellschaft für Nuklearmedizin (OGN), and Schweizerische Gesellschaft für Nuklearmedizin (SGNM). This guidance is based on an interdisciplinary consensus. These recommendations are a prerequisite for the quality management in the treatment of patients with bone metastases from prostate cancer using (223)Ra. They are aimed at guiding nuclear medicine specialists in selecting candidates to receive therapy and to deliver the treatment in a safe and effective manner. The document contains background information and definitions. It covers the rationale, indications and contraindications for therapy with (223)Ra. Essential topics are the requirements for institutions performing the therapy, which patient data have to be available prior to performance of therapy, and how treatment has to be carried out technically and organisationally. Moreover, essential elements of follow-up and aftercare are specified. As a matter of principle, the treatment inclusive aftercare has to be realised in close cooperation with the involved medical disciplines.
authors.affiliation: Dr. Thorsten Pöppel, Universitätsklinikum Essen, Klinik für Nuklearmedizin, Hufelandstr. 55, 45122 Essen, Thorsten.Poeppel@uk-essen.de.
authors.forename: Thorsten D
authors.initials: TD
authors.lastname: Pöppel
authors.forename: Michael
authors.initials: M
authors.lastname: Andreeff
authors.forename: Alexander
authors.initials: A
authors.lastname: Becherer
authors.forename: Andreas
authors.initials: A
authors.lastname: Bockisch
authors.forename: Eva
authors.initials: E
authors.lastname: Fricke
authors.forename: Lilli
authors.initials: L
authors.lastname: Geworski
authors.forename: Alexander
authors.initials: A
authors.lastname: Heinzel
authors.forename: Bernd J
authors.initials: BJ
authors.lastname: Krause
authors.forename: Thomas
authors.initials: T
authors.lastname: Krause
authors.forename: Markus
authors.initials: M
authors.lastname: Mitterhauser
authors.forename: Klemens
authors.initials: K
authors.lastname: Scheidhauer
authors.forename: Marcus
authors.initials: M
authors.lastname: Schenck
authors.forename: Wilfried
authors.initials: W
authors.lastname: Sonnenschein
authors.forename: Michael
authors.initials: M
authors.lastname: Gabriel
mesh_terms: D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D019317:Evidence-Based Medicine; D005858:Germany; D009683:Nuclear Medicine / Q000592:standards*; D017410:Practice Guidelines as Topic; D019275:Radiopharmaceuticals / Q000592:standards / Q000627:therapeutic use; D011878:Radiotherapy / Q000592:standards*; D011883:Radium / Q000592:standards / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D011883:Radium
keywords: Radionuclide therapy; Radium-223; alpha emitter; bone metastases; prostate cancer